The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
Cervical cancer during pregnancy can be successfully managed with a multidisciplinary treatment team and an individualized treatment strategy that optimizes maternal treatment while considering fetal safety. Read More ›
In October 2021, the FDA approved the immunotherapy Keytruda (pembrolizumab), in combination with chemotherapy and with or without Avastin (bevacizumab), for patients with persistent, recurrent, or metastatic cervical cancer and PD-L1 expression. Read More ›
In September, the FDA approved Tivdak (tisotumab vedotin) for the treatment of women with recurrent or metastatic cervical cancer that progressed during or after chemotherapy. This is the first tissue factor–directed antibody and microtubule inhibitor conjugate approved for women with advanced cervical cancer. Read More ›
HPV infection is the most common sexually transmitted disease and the cause of several types of cancer, including anal cancer. Several experts explain the effectiveness of the HPV vaccine in preventing these cancers, something that we should all be aware of. Read More ›
Jacky Costello details how her cancer journey has scarred her but ultimately made her stronger, which taught her valuable lessons about seeking support from others and finding strength through change. Read More ›